ViRexx treats first volunteer in phase 1 clinical study of hepatitis B vaccine

By Lisa Kerner

Charlotte, N.C., June 15 - ViRexx Medical Corp. said the first of 15 volunteers in a phase 1 safety study of HepaVaxx B vaccine for hepatitis B has been treated at the McGill University Health Centre's Vaccine Study Centre.

"The initiation of the HepaVaxx B vaccine trial represents the third platform technology from ViRexx to enter the clinic," chief executive officer Lorne Tyrrell said in a company news release.

"The outcome of HepaVaxx B vaccine study will provide important information on the safety profile of this Chimigen vaccine in humans."

ViRexx said the HepaVaxx B vaccine, which targets dendritic cells, consists of a recombinant chimeric molecule including a hepatitis B viral antigen and a portion of a murine monoclonal antibody.

Located in Edmonton, Alta., ViRexx develops novel therapeutic products for the treatment of cancers and chronic viral infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.